Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines

Advanced or recurrent low-grade serous ovarian cancers (LGSC) are resistant to conventional systemic treatments. LGSC carry mutations in RAS or RAF, leading to several clinical trials evaluating MEK inhibitors (MEKi). As LGSC cell lines and xenografts have been difficult to establish, little is know...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Am J Cancer Res
Autores principales: Fernández, Marta Llauradó, DiMattia, Gabriel E, Dawson, Amy, Bamford, Sylvia, Anderson, Shawn, Hennessy, Bryan T, Anglesio, Michael S, Shepherd, Trevor G, Salamanca, Clara, Hoenisch, Josh, Tinker, Anna, Huntsman, David G, Carey, Mark S
Formato: Artigo
Lenguaje:Inglês
Publicado: e-Century Publishing Corporation 2016
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5088288/
https://ncbi.nlm.nih.gov/pubmed/27822414
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares